Company profile
Janux Therapeutics, Inc.
NASDAQ: JANX · Healthcare · Biotechnology
#630 of 1,418 Healthcare companies by revenue35th-percentile growth
EA Score
54DFH 59DQ 52GM 44SS 54
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, operating margin
Methodology →Revenue TTM
$31.9M
Rev growth YoY (TTM)
+7162.0%
Net income (FY)
-$113.6M
Employees
108
as of 2026-08-10
Market cap
$966.6M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$10.0M$10.0M2025
Net income-$113.6M-$113.6M2025
Operating income-$157.7M-$157.7M2025
Total assets$1.0B$1.0B2025
Liabilities$44.7M$44.7M2025
Equity$956.8M$956.8M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Janux Therapeutics, Inc.’s revenue?
Janux Therapeutics, Inc. booked $10.0M in FY2025 revenue, contracting 5.6% year over year — slower than 65% of Healthcare companies we track, at a -1136.3% net margin.
Peers · Healthcare
Alpha Cognition Inc39DKhiron Life Sciences Corp.——Zenas BioPharma, Inc.33DSyros Pharmaceuticals, Inc.——Stablecoin Development Corp.44DTaysha Gene Therapies, Inc.48DNeighbors
San Diego →Key facts
CEODavid Alan Campbell
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: JANX
Employees108
IPO date2021-06-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.